Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques

World Journal of Hepatology

Volumn 6, Issue 12, 2014, Pages 844-850

  Imai, Norihiro ^a   Ishigami, Masatoshi ^a   Ishizu, Yoji ^a   Kuzuya, Teiji ^a   Honda, Takashi ^a   Hayashi, Kazuhiko ^a   Hirooka, Yoshiki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Balloon occluded transcatheter arterial chemoembolization; Drug eluting bead; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

Indexed keywords

EID: 84920045180     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i12.844     Document Type: Article

References (59)

1. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109: 542-553 [PMID: 24513805 DOI: 10.1038/ajg.2014.11].
2. Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model. Liver Int 2011; 31: 692-699 [PMID: 21457441 DOI: 101111/j.1478-3231.2011.02480.x].
3. Ikeda K, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Prevention of disease progression with antiinflammatory therapy in patients with HCV-related cirrhosis: a Markov model. Oncology 2014; 86: 295-302 [PMID: 24924385 DOI: 10.1159/000357713].
4. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401 [PMID: 6306721 DOI: 10.1148/radiology.148.2.6306721].
5. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988; 94: 453-456 [PMID: 2826285].
6. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68: 2150-2154 [PMID: 1655202].
7. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X].
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156].
9. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54 [PMID: 12091661 DOI: 10.1148/radiol.2241011262].
10. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469 [PMID: 16890600 DOI: 101053/j.gastro.2006.05.021].
11. Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol 2013; 24: 490-500 [PMID: 23466316 DOI: 10.1016/j.jvir.2013.01.003].
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199].
13. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-685 [PMID: 20633193 DOI: 10.1111/j.1872-034X.2010.00673.x].
14. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392 [PMID: 2946403].
15. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, Maeda M, Yoshioka T. Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1990; 13: 140-145 [PMID: 2171772].
16. Demachi H, Matsui O, Abo H, Tatsu H. Simulation model based on non-newtonian fluid mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug. Cardiovasc Intervent Radiol 2000; 23: 285-290 [PMID: 10960542].
17. Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over. 15. years at a single center. AJR Am J Roentgenol 2008; 190: 608-615 [PMID: 18287429 DOI: 10.2214/AJR.07.2879].
18. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83 [PMID: 8390073 DOI: 10.1148/radiology.188.1.8390073].
19. Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2009; 39: 346-354 [PMID: 19054145 DOI: 10.1111/j.1872-034X.2008.00466.x].
20. Wallace MJ, Murthy R, Kamat PP, Moore T, Rao SH, Ensor J, Gupta S, Ahrar K, Madoff DC, McRae SE, Hicks ME. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol 2007; 18: 1500-1507 [PMID: 18057284 DOI: 10.1016/j.jvir.2007.07.021].
21. Kakeda S, Korogi Y, Ohnari N, Moriya J, Oda N, Nishino K, Miyamoto W. Usefulness of cone-beam volume CT with flat panel detectors in conjunction with catheter angiography for transcatheter arterial embolization. J Vasc Interv Radiol 2007; 18: 1508-1516 [PMID: 18057285 DOI: 10.1016/j.jvir.2007.08.003].
22. Nakamura H, Hashimoto T, Oi H, Sawada S, Furui S, Mizumoto S, Monden M. Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins. Acta Radiol 1990; 31: 347-349 [PMID: 2169828].
23. de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, Dufaux J, Lumbroso J, Rougier P, Ducreux M, Roche A. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996; 201: 731-735 [PMID: 8939223 DOI: 10.1148/radiology.201.3.8939223].
24. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, Moriyama N, Okusaka T, Okada S, Ueno H. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176: 681-688 [PMID: 11222205 DOI: 10.2214/ajr.176.3.1760681].
25. Toyoda H, Kumada T, Sone Y. Impact of a unified CT angiography system on outcome of patients with hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192: 766-774 [PMID: 19234276 DOI: 10.2214/AJR.08.1368].
26. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18: 365-376 [PMID: 17377182 DOI: 10.1016/j.jvir.2006.12.004].
27. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Takata H, Takeda T, Aburano H, Shigenari N. Iodized oil accumulation in the hypovascular tumor portion of early-stage hepatocellular carcinoma after ultraselective transcatheter arterial chemoembolization. Hepatol Int 2007; 1: 451-459 [PMID: 19669342 DOI: 10.1007/s12072-007-9030-5].
28. Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, Yoshie Y, Sanada T, Notsumata K, Tanaka N, Matsui O. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009; 39: 374-381 [PMID: 19054146 DOI: 10.1111/j.1872-034X.2008.00465.x].
29. Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol 2013; 24 509-517 [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013].
30. Irie T, Takahashi N. Improved accumulation of lipiodol under balloon-occluded transarterial chemoembolization (BTACE) for hepatocellular carcinoma: measurement of blood pressure at the embolized artery before and after balloon inflation. IVR 2009; 26: 49-54.
31. Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 2013; 36: 706-713 [PMID: 22996589 DOI: 10.1007/s00270-012-0476-z].
32. Sahara S, Tanihata H, Sato M, Kawai N, Takasaka I, Minamiguchi H, Nakai M, Sonomura T. Effects of hepatic artery chemoembolization using cisplatin-lipiodol suspension with gelatin sponge particles on swine liver. J Vasc Interv Radiol 2009; 20: 1359-1364 [PMID: 19695901 DOI: 10.1016/j.jvir.2009.06.028].
33. Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K, Chayama K. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 32: 687-694 [PMID: 19444503 DOI: 10.1007/s00270-009-9570-2].
34. Osuga K, Arai Y, Anai H, Takeuchi Y, Aramaki T, Sugihara E, Yamamoto T, Inaba Y, Ganaha F, Seki H, Sadaoka S, Sato M, Kobayashi T, Kodama Y, Inoh S, Yamakado K. Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401. J Vasc Interv Radiol 2012; 23: 1278-1285 [PMID: 22922041 DOI: 10.1016/j.jvir.2012.06.028].
35. Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, Kim YJ, Lee HS, Jae HJ, Park JH. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol 2013; 24: 274-283 [PMID: 23369561 DOI: 10.1016/j.jvir.2012.11.002].
36. Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study. Gut Liver 2013; 7: 576-584 [PMID: 24073316 DOI: 10.5009/gnl.2013.7.5.576].
37. Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 2011; 80: 188-194 [PMID: 21709428 DOI: 10.1159/000328749].
38. Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2012; 30: 2015-2025 [PMID: 22187203 DOI: 10.1007/s10637-011-9776-4].
39. Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 2011; Epub ahead of print [PMID: 21976133 DOI: 10.1007/s00535-011-0475-x].
40. Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Intervent Radiol 2012; 35: 82-89 [PMID: 21203761 DOI: 10.1007/s00270-010-0086-6].
41. Kawaoka T, Aikata H, Katamura Y, Takaki S, Waki K, Hiramatsu A, Takahashi S, Hieda M, Kakizawa H, Chayama K. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 1219-1225 [PMID: 20619676 DOI: 10.1016/j.jvir.2010.04.014].
42. Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, Toshima F, Matsui O. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol 2012; 30: 263-270 [PMID: 22223074 DOI: 10.1007/s11604-011-0043-6].
43. Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 2013; 43: 942-949 [PMID: 23301851 DOI: 10.1111/hepr.12041].
44. Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc Intervent Radiol 2013; 36: 1023-1029 [PMID: 23238851 DOI: 10.1007/s00270-012-0537-3].
45. Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Transcatheter arterial chemotherapy using miriplatinlipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2012; 42: 175-182 [PMID: 22210921 DOI: 10.1093/jjco/hyr189].
46. Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. Gut Liver 2013; 7: 246-251 [PMID: 23560163 DOI: 10.5009/gnl.2013.7.2.246].
47. Bilbao JI, de Luis E, García de Jalón JA, de Martino A, Lozano MD, de la Cuesta AM, Sangro B. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008; 19: 1625-1638 [PMID: 18823795 DOI: 10.1016/j.jvir.2008.07.014].
48. Osuga K, Hori S, Hiraishi K, Sugiura T, Hata Y, Higashihara H, Maeda N, Tomoda K, Nakamura H. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol 2008; 31: 1108-1116 [PMID: 18543028 DOI: 10.1007/s00270-008-9369-6].
49. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35 980-985 [PMID: 22009576 DOI: 10.1007/s00270-011-0287-7].
50. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, Bargellini I, Petruzzi P, Massa Saluzzo C, Crespi S, Sarti I. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31: 1141-1149 [PMID: 18696150 DOI: 10.1007/s00270-008-9409-2].
51. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, Leppard SW, Wolfenden LC, Palmer RR, Stratford PW. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17: 335-342 [PMID: 16517780 DOI: 10.1097/01.RVI.0000195323.46152.B3].
52. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7].
53. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197: W562-W570 [PMID: 21940527 DOI: 10.2214/AJR.10.4379].
54. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552 [PMID: 21849247 DOI: 10.1016/j.jvir.2011.07.002].
55. Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol 2011; 34: 557-565 [PMID: 20821211 DOI: 10.1007/s00270-010-9975-y].
56. Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2012; 35: 555-562 [PMID: 21562932 DOI: 10.1007/s00270-011-0176-0].
57. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250 [PMID: 22824821 DOI: 10.1016/j.jhep.2012.07.017].
58. Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17: CR189-CR195 [PMID: 21455104].
59. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480 [PMID: 20213741 DOI: 10.1002/jso.21522].